## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($311.80)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Stockholders to Inquire about Securities Investigation**
- Source: KTLA | 20251202T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Elevance Health, Inc. (NYSE: ELV) on behalf of investors who purchased securities prior to April 18, 2024. The investigation aims to determine if Elevance and its officers/directors engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for more information and to assist in the investigation, offering representation on a contingency fee basis.

**2. Quadrant Capital Group LLC Cuts Stock Position in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251202T020915 | Somewhat-Bullish | Relevance: 99%
-  Quadrant Capital Group LLC reduced its stake in Elevance Health, Inc. by 25.5% in the second quarter, selling 948 shares to hold 2,769 shares valued at $1.08 million. Despite this reduction by one firm, other large institutional investors like Vanguard, Sanders Capital, Nuveen, Orbis Allan Gray, and Boston Partners increased their positions in the company, with institutional ownership reaching 89.24%. Elevance Health also reported strong Q3 earnings, beating analyst expectations for both EPS and revenue, and declared a quarterly dividend of $1.71.

**3. North Peak Capital Management LLC Purchases 115,460 Shares of Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251202T020915 | Bullish | Relevance: 99%
-  North Peak Capital Management LLC boosted its stake in Elevance Health, Inc. by 40.3% in the second quarter, acquiring an additional 115,460 shares, bringing its total to 401,670 shares valued at approximately $156.23 million. This makes Elevance Health the fourth-largest position in North Peak's portfolio, representing 12.3% of its investments. Elevance Health reported strong earnings with $6.03 EPS, exceeding consensus estimates, and declared a quarterly dividend of $1.71 per share.

**4. Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Stockholders to Inquire about Securities Investigation**
- Source: WBOY.com | 20251202T110000 | Neutral | Relevance: 98%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. (NYSE:ELV) securities. The investigation concerns whether the company and its officers/directors engaged in corporate wrongdoing. Stockholders who purchased shares before April 18, 2024, and still hold them, are encouraged to contact the firm for more information.

**5. Bronstein, Gewirtz & Grossman, LLC Encourages Elevance Health, Inc. (ELV) Stockholders to Inquire about Securities Investigation**
- Source: ABC4 Utah | 20251202T110000 | Neutral | Relevance: 98%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elevance Health, Inc. (NYSE:ELV). The investigation focuses on whether Elevance and its officers engaged in corporate wrongdoing. Stockholders who purchased shares prior to April 18, 2024, are encouraged to contact the firm for more information.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-26 | TD Cowen | $400 | $380 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-26 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Long-term trend broken: trading 8.0% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.88 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $76.8B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.88 |
| Forward P/E | 12.2 |
| Current P/E | 11.0 |
| YoY Growth | -9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.9% to -2.0% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. MACD histogram positive (1.72), confirming momentum. RSI neutral at 52.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.98% (CS: 37) | Neutral |
| RSI_14 | 51.8 | Neutral |
| MACD Histogram | 1.72 | Bullish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 0.993x | Below |
| vs SMA200 | 0.920x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $330.92
- **Stop Loss:** $311.80 (5.8% risk)
- **Target:** $350.04 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 52
- **Position Value:** $17,207.84
- **Portfolio %:** 17.21%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*